Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer
Authors:
- 16 November 2017
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 34 (12) , 2566-2584
Abstract
Introduction A major treatment goal for advanced breast cancer (ABC) is to maintain or ideally improve patient quality of life (QoL). Given the changing disease landscape, this systematic literature review (SLR) aims to assess the impact of endocrine therapies (ET), including ET monotherapy (ET mono) and ET combined with targeted therapy (ET + TT), on QoL of women with HR+/HER2− ABC. Methods A SLR was conducted to identify randomized controlled trials (RCTs) meeting the following criteria: (1) included ET mono or ET + TT, (2) reported QoL outcomes, (3) focused on women with HR+/HER2− ABC, and (4) published after 2007 (when standardized HER2 testing became available). The databases searched included MEDLINE, EMBASE, Cochrane Library, and key conference proceedings from 2013 to 2016. QoL outcomes for ET mono, ET + TT, and comparisons between the two were summarized from the identified trials. Results A total of 11 studies (representing 6 RCTs) were identified. The study populations included first-line (5 studies) and ET-failure settings (6 studies). Across settings, global health status (GHS) maintained or deteriorated slightly on these treatments during the trial period. Time to deterioration (TTD) in QoL measured by GHS was analyzed in 6 studies and 4 RCTs. In the first-line setting, reported median TTD in GHS was similar between ET mono and ET + TT (7.2–13.8 months in ET mono; 11.1 months in ET + TT). In the ET-failure setting, ET + TT showed significantly longer TTD vs. ET mono in GHS (median 5.6–8.4 months in ET mono and 8.3–11.7 months in ET + TT) and some additional domains. Conclusions ET + TT users experienced similar QoL in the first-line and ET-failure setting relative to patients on ET mono. Moreover, ET + TT users experienced better QoL outcomes in some domains in the ET-failure setting relative to ET mono users. Funding Novartis.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 38 references indexed in Scilit:
- Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trialSupportive Care in Cancer, 2013
- Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trialsCancer Treatment Reviews, 2011
- Benefits and adverse effects of endocrine therapyAnnals of Oncology, 2010
- New Strategies in Estrogen Receptor–Positive Breast CancerClinical Cancer Research, 2010
- Quality of life in patients with breast cancer before and after diagnosis: an eighteen months follow-up studyBMC Cancer, 2008
- The influence of endocrine treatments for breast cancer on health-related quality of lifeCancer Treatment Reviews, 2008
- Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007Journal of Experimental & Clinical Cancer Research, 2008
- Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT RecommendationsThe Journal of Pain, 2008
- Extending Survival with Chemotherapy in Metastatic Breast CancerThe Oncologist, 2005
- A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scaleJournal of Clinical Epidemiology, 2004